The Melanoma Nursing Initiative https://validator.w3.org/feed/docs/rss2.html Spain The Melanoma Nursing Initiative – Home HCP Toolkits Immunotherapy in Hepatitis B carriers Italy Germany France ctDNA Patient Handout TIL Therapy Spot Check for Melanoma: Final Thoughts Non-Invasive Genetic Sticker EVALUATION OF SUSPICIOUS SPOTS RISK FACTORS FOR MELANOMA Options for Stage II Melanoma: Making the Decision That’s Right For You Checkpoint Inhibitor Response Monitoring: Timely Guidance Using ctDNA Contact Options for Stage III Melanoma Canada UK Australia News Terms of Use Reply To: Esophagitis Reply To: mucositis & mouth sores from Nivo Samantha R. Guild, J.D. MNI Leadership Board Oncolytic Viruses Portugal Reply To: Esophagitis THE BENEFITS OF EARLY DETECTION OF MELANOMA What do you tell patients with Stage IIA melanoma who are worried about their risk of recurrence? How do you weigh the benefits and risks of adjuvant therapy vs active surveillance? How is adjuvant therapy given? What are the side effects of adjuvant therapy? What is Stage II melanoma? Is Stage II melanoma at high risk for coming back (recurring)? How can I lower my risk for Stage II melanoma coming back? What adjuvant drugs are used? Is it true that Stage II melanoma can have a worse prognosis than Stage III melanoma? SPOT CHECK FOR MELANOMA: EXPLORING NON-INVASIVE OPTIONS About International Resources HCP Consensus Statements Patient Action Plans Stage IV Melanoma Treatment Options BRAF Q&A BRAF Testing Patient Videos HCP Videos Education Care Step Pathways